Kringle Pharma, Inc.

2026/09/16 Updated
Market Cap: $22.7M (¥3.5B)
Stock Price: $2.81 (¥436)
Exchange Rate: 1 USD = ¥155.04

Notice of Exercise Completion of the 16th Stock Acquisition Rights Issued Through Third-Party Allotment (Exercise Price Adjustment Provisions) and Monthly Exercise Status

announces the completion of the exercise of the 16th stock acquisition rights. For the monthly exercise status, 2,100 rights were exercised against 210,000 shares issued, representing 12.4% of total issued rights. Total issued shares: 8,383,200; unexercised rights: 0. As of August 27.

Importance:
Page Updated: August 27, 2026
IR Disclosure Date: August 27, 2026

Key Figures

  • Allocated shares: 210,000 shares
  • Total issuing stock acquisition rights: 17,000 rights
  • Number of exercised stock acquisition rights: 2,100 rights

AI要約

Overview

Today, we announce the completion of all exercises of the 16th stock acquisition rights issued through third-party allotment with exercise price adjustment provisions. In the monthly exercise status, 2,100 rights were exercised against 210,000 allocated shares, with an exercise rate of 12.4% of the total issued rights. Unexercised shares stand at 0, and the total exercise ratio records 3.1%.

Impact going forward

Total issued shares are 8,383,200 (including 183 treasury shares). The completion of this exercise is expected to have a limited dilutive impact. All monthly exercise status for August 2026 has been completed, and we will continue to disclose stock option management status.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Klinglea Pharma Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →